MSD Signs an Exclusive License and Research Agreement with Themis Bioscience to Develop Vaccine Therapies
Shots:
- MSD enters into a research collaboration and exclusive license agreement for the discovery and development of undisclosed vaccine candidates utilizing Themis’ measles virus vector-based platform
- Themis to receive ~200M development and commercial milestones and royalties on approved products from the agreement. MSD to provide research funding and make an equity investment in Themis
- Themis licenses its measles virus vector-based platform from the Pasteur Institute in Paris- incorporating large recombinant genes coding for selected antigens into its genome
Click here to read full press release/ article | Ref: Themis Bioscience | Image: Guide-Post Solutions
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com